1	Original Article
---	-------------------------

- 2 Title
- 3 Adherence to methotrexate and associated factors considering social desirability in patients
- 4 with rheumatoid arthritis: a multicenter cross-sectional study
- 6 Authors

- 7 Nobuyuki Yajima, MD, MPH, PhD^{1,2,3}; Takashi Kawaguchi, PhD⁴; Ryo Takahashi, MD¹;
- 8 Hiroki Nishiwaki, MD, MPH, PhD 5,6; Yoichi Toyoshima, MD, PhD (ORCID ID,
- 9 0000-0002-6097-2552)⁷; Koei Oh, MD, PhD ⁸; Tsuyoshi Odai, MD, PhD ^{9.10}; Takayuki Kanai,
- 10 MD, PhD ¹¹; Donald E. Morisky, ScD, MSPH¹²; Takuhiro Yamaguchi, PhD¹³; Tsuyoshi
- 11 Kasama, MD, PhD (ORCID ID, 0000-0002-3871-6456)
- 12 **Affiliations**
- 13 Division of Rheumatology, Department of Medicine, Showa University School of Medicine,
- 14 Tokyo, Japan
- ² Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine
- and Public Health, Kyoto, Japan
- 17 ³ Center for Innovative Research for Communities and Clinical Excellence, Fukushima

- 18 Medical University, Fukushima, Japan
- 19 ⁴ Department of Practical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy
- and Life Sciences, Tokyo, Japan
- ⁵ Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka
- 22 Hospital, Yokohama, Japan
- ⁶ Showa University Research Administration Center, Tokyo, Japan
- ⁷ Department of Orthopedic Surgery, Showa University Toyosu Hospital, Tokyo, Japan
- ⁸ Department of Orthopedic Surgery, Showa University Northern Yokohama Hospital,
- 26 Yokohama, Japan
- 27 ⁹ Department of Internal Medicine, Showa University Northern Yokohama Hospital,
- 28 Yokohama, Japan
- 29 Department of Rheumatology, Yokohama Asahi Central General Hospital, Kanagawa,
- 30 Japan.
- 31 Department of Nephrology, Kanto Rosai Hospital, Kawasaki, Japan
- 32 12 Department of Community Health Sciences, UCLA Fielding School of Public Health
- 33 livision of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan
- 34 Corresponding author:

35 Nobuyuki Yajima

- 36 Division of Rheumatology, Department of Medicine, Showa University School of Medicine,
- 37 Tokyo, Japan
- 38 Address:1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
- 39 Phone: +81-3-3784-8942; Fax:+81-3-3784-8946
- 40 E-mail: n. yajima@med. showa-u. ac. jp
- 41 ORCID iD: 0000-0002-8292-3962
- 43 **Abstract**

42

- 44 **Background**: Assessing medication adherence in rheumatoid arthritis (RA) is clinically
- 45 significant as low adherence is associated with high disease activity. Self-reported medication
- adherence surveys have been shown to have problems with overestimation of adherence due
- 47 to social desirability bias. However, no MTX adherence studies adjusted for social
- desirability have been conducted to date. This study aimed to evaluate adherence to MTX and
- 49 perform an investigatory search for factors associated with MTX adherence including social
- 50 desirability.
- 51 **Methods**: This cross-sectional multicenter study was conducted among adult RA patients

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

consuming oral MTX for ≥3 months. We examined the distribution of MTX adherence, according to the eight-item Morisky Medication Adherence Scale (MMAS-8). Furthermore, an exploratory factor analysis involving social desirability was examined to identify factors associated with MTX adherence using linear regression analysis. To deal with missing values, we used multiple imputations with chained equations methods. **Results**: A total of 165 RA patients were enrolled. The median age was 64 years, and 86.1% were women. Based on the MMAS-8, low, medium, and high adherences were noted in 12.1%, 60.0%, and 27.9% of participants, respectively. High social desirability (coefficient, 0.14; 95% confidence interval [CI], 0.05–0.23; p<0.05) and high age (coefficient per 10 years, 0.16; 95% CI, 0.01–0.03; p<0.05) were associated with high MTX adherence, whereas full-time work was negatively associated with high MTX adherence (coefficient, -0.50; 95% CI, -0.95--0.05; p<0.05). Conclusions: Sixty percent of RA patients had medium adherence to MTX. High social desirability, high educational level, and non-full-time work may be associated with high MTX adherence. Physicians should confirm MTX adherence before switching or adding disease-modifying anti-rheumatic drugs in cases of uncontrolled disease activity. **Keywords:** rheumatoid arthritis, methotrexate, drug monitoring

70

85

86

Background 71 Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic 72 inflammation. RA affects the joints and leads to functional disability in the absence of 73 appropriate treatment [1]. The 2015 American College of Rheumatology (ACR) and the 74 2019 European League against Rheumatism recommendations suggested the early use 75 of disease-modifying antirheumatic-drugs (DMARDs), usually methotrexate (MTX), in 76 most active RA patients [2,3]. Several studies have reported that low medication 77 adherence is associated with high RA disease activity [4,5]. Hence, MTX adherence in 78 RA patients is crucial. 79 Several studies on adherence to MTX have been conducted. However, MTX adherence 80 differed among the studies because of the various definitions of adherence, different 81 follow-up durations, and heterogeneity of patient populations. A previous study reported 82 that MTX adherence is associated with age, sex, race, RA disease activity, patient 83 beliefs about the medication, disease duration, mental health, and socio-economic status 84 (SES) [4,6–10]. In a systematic review, beliefs on the necessity and efficacy of MTX,

absence of low mood, mild disease, and MTX monotherapy were identified as the most

reliable variables related to MTX adherence [11].

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

Social desirability is well known to influence the use of self-reported questionnaires in research. A previous study reported that social desirability is the tendency to respond to self-reported items in a way that reflects better on the respondent rather than acting accurately and truthfully [12]. Self-reported medication adherence surveys have been shown to have problems with overestimation of adherence due to social desirability bias [13,14]. A previous MTX adherence study has reported the need to control this bias [15]; however, no studies have investigated the MTX adherence survey by controlling for social desirability. Thus, this study aimed to evaluate the adherence of RA patients to MTX and exploratively evaluate factors associated with MTX adherence with the addition of social desirability. Methods Study design This cross-sectional study was conducted in four hospitals: Showa University Hospital, Showa University Northern Yokohama Hospital, Showa University Fujigaoka Hospital, and Kanto Rosai Hospital. Patient population

Participants were outpatients who met the 2010 ACR criteria for RA [16]. The inclusion criteria were age ≥20 years and consumption of oral MTX for ≥3 months. The exclusion criteria were patients with dementia, restlessness, and severe psychiatric disorders. Sequential sampling was employed. Patients were recruited between August 2013 and October 2014.

Data collection

RA disease activity was assessed using the Disease Activity Score in 28 joints (DAS28-ESR). DAS28 provides a global summative and continuous score for disease activity assessment and has been widely used in clinical trials and practice [17]. Activities of daily living (ADL) was assessed using the modified Health Assessment Questionnaire (mHAQ), which is a self-reported questionnaire that measures function, including ADL performance. Depression state was defined using the Centre for Epidemiological Studies-Depression (CES-D) scale, which includes a 20-item questionnaire; the scores range from 0 to 60. We determined that a total score of ≥16 describes a depressive state [18]. The patient's perceptions towards medications were assessed using the Belief about Medicines Questionnaire-Specific (BMQ-specific),

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

which includes two domains, BMQ-Specific necessity (5 items) and BMQ-Specific concern (5 items). The responses are recorded on a 5-point Likert Scale (ranging from 1=strongly disagree to 5=strongly agree). The score by domains ranges from 5 to 25; higher scores indicate stronger beliefs in the concepts represented by the scale. We used **BMQ** necessity-concern differential ("BMQ-Specific necessity" the minus "BMQ-Specific concern") which shows appropriate reliability and was used in numerous studies in multivariable analysis [19]. Pain severity was assessed using the Brief Pain Inventory (BPI). Moreover, we measured the following: worst numerical rating scale (NRS) pain score, least NRS pain score, average NRS pain score, and current NRS pain score. We used the average NRS pain score other clinical studies have applied in the multivariable analysis. Social desirability is typically assessed using the Social Desirability Scale (SDS) developed by Crowne and Marlowe in 1960, with 33 items [20]. Furthermore, a 13-item SDS was developed with confirmed validity and reliability [21]. In this study, we used the 13-item SDS. Short Form-8 (SF-8) is a health-related quality of life (QoL) questionnaire, which measures the same eight health domains (physical functioning, role physical, bodily pain, general health, vitality, social

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

functioning, role emotional, and mental health) similar to Short Form-36 (SF-36v2®) but shorter, using eight questions and whose validity and reliability were confirmed [22]. This questionnaire was used to assess the QoL in RA [23]. The score range of each domain is from 0 to 100; higher scores suggest better health-related QoL. We used two summary scores: mental component summary (MCS; showing mental status) and physical component summary (PCS; showing physical status). The Japanese versions of mHAQ, CES-D, BMQ, BPI, SDS, and SF-8 were validated [24,25]. Additionally, we obtained data on SES, including marital status, educational level, employment status, and living status. Data on patient characteristics, medication, and SES were further collected using questionnaires. Other data were obtained from medical chart records. After consulting the doctor, the participants answered the Morisky Medication Adherence Scale (MMAS-8), mHAQ, CES-D, BMQ, BPI, SDS, SF-8, and SES questionnaires; they returned the completed questionnaires to the data center by mail. Outcome The primary outcome was the distribution of MTX adherence according to MMAS-8

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

at the time of the survey based on the patient's description. MMAS-8 consists of an eight-item questionnaire [26-28]. MMAS-8 scores range from 0 to 8 and are classified as follows: low, <6; medium, >6 and <8; and high, 8. Originally, MMAS-8 was developed for daily administration of oral medicine. MTX was administered once a week; thus, we developed the Japanese questionnaire for MTX accordingly. First, we translated the questionnaire from English to Japanese and resolved some language discrepancies. Second, back translations were performed. Third, we discussed the questionnaire and achieved a consensus. Finally, a pre-test in five RA patients followed by necessary modifications were performed to finalize the Japanese questionnaire. Statistical analyses MMAS-8, sex, CES-D, and SES were used as categorical variables, whereas age, MTX dose, MTX dosing frequency, duration of MTX treatment, disease duration, DAS28-ESR, mHAQ, BMQ, BPI, SDS, and SF-8 were used as continuous variables. Summary statistics were presented as median with interquartile range (IQR) and numbers with proportion (%). First, we evaluated the distribution of MTX adherence according to MMAS-8. Subsequently, we compared MMAS-8 and pre-described factors

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

using one-way analysis of variance (ANOVA), Kruskal-Wallis test, and chi-squared test. For significant factors, we conducted a trend analysis. Finally, multiple linear regression analysis was performed to exploratively assess factors associated with MTX adherence with the addition of social desirability. The co-variables selected were as follows: age, sex, disease duration, RA disease activity (DAS28-ESR), depression state (CES-D), reliability of the medication (BMQ necessity-concern differential), social desirability (SDS), educational level (more than, equal to college-level, or not), and employment status (full-time work or not). These factors were further selected based on previous studies and clinical importance [4,6–10,29–31]. This was an observational study; hence, the sample size was not calculated on a statistical basis but was measured to the extent practicable over the study period. To compare the mean DAS-28 scores among the three groups using ANOVA, the effect size (small, 0.1; medium, 0.25; and large: 0.4) customarily proposed by Cohen [32] was set at medium (0.25), the significance level was set at 5% on both sides, and the power was set at 80%. The total number of cases was calculated to be 159. The target number of cases was 176, assuming a dropout rate of 10%.

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

To deal with missing values, we used multivariable multiple imputations with chained equations methods to increase power and minimize selection bias. We included age, sex, disease duration, RA disease activity, depression state, reliability of the medication, social desirability, educational level, and employment status for each imputation model. We generated 10 imputed datasets and combined coefficient estimates using Rubin's rules for each imputation. Imputation of missing data in this way assumes that data were missing at random since any reasons for missing were explained by the observed variables included in the imputation model. A two-sided p-value <0.05 was considered statistically significant. All statistical analyses were conducted using STATA 14.2 (StataCorp LP, College Station, TX) software. Ethical considerations The ethics committee of Showa University Hospital (approval number 1446) and Showa University Toyosu Hospital, Showa University Northern Yokohama Hospital, Kanto Rosai Hospital approved this study, and informed consent was obtained from all participants before study enrolment. All study procedures were performed in accordance

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

with the Declaration of Helsinki. Patient information was anonymized and de-identified before analysis. **Results** Patient flow chart Figure 1 shows the patient flow chart. Initially, 181 RA patients were invited. Of 169 patients eligible for the study, four were excluded because of missing MTX adherence data (n=2) and clinical data (n=2). A total of 165 RA patients were included in the final analysis. Baseline characteristics The characteristics of the participants are shown in Table 1. The median age of the patients was 64 years (IQR, 54-72), and 86.1% were women. The median dose of MTX was 8 mg per week (IQR, 6-12), median MTX dosing frequency was three times per week (IQR, 2-3), and median duration of MTX treatment was 36 months (IQR, 17-75). The proportion of missing data varied from 0 to 15.2% (Supplementary table 1). **INSERT TABLE 1 HERE** Distribution of MTX adherence

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

Based on MMAS-8, low, medium, and high adherence rates were noted in 12% (20/165), 60% (99/165), and 28% (46/165) of cases, respectively. The median MMAS-8 score was 7 (IQR, 6.5–8). Patient's characteristics by grade of MTX adherence Patient's characteristics by grade of MTX adherence divided by MMAS-8 are shown in Table 1. A significant association between levels of MTX adherence and age, mHAQ, SDS, SF-8 (PCS), and employment status was found. Based on trend analysis, older participants had significantly high adherence, and the higher the social desirability, the higher the adherence. However, a significant association between MTX adherence and mHAQ and SF-8 (PCS) was not observed in the trend analysis. Factors associated with high MTX adherence considering social desirability In the multiple linear regression analysis adjusted for age, sex, disease duration, RA disease activity (DAS28-ESR), depression state (CES-D), reliability of the medication (BMQ necessity-concern differential), social desirability (SDS), educational level (more than or equal to college-level or not), and employment status (full-time work or not), higher social desirability (coefficient, 0.14; 95% confidence interval [CI], 0.05–0.23;

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

p<0.05) and higher age (coefficient per 10 years, 0.16; 95% CI, 0.01–0.03; p<0.05) were associated with high MTX adherence, whereas full-time work was negatively related to high MTX adherence (coefficient, -0.50; 95% CI, -0.95--0.05; p<0.05) (Table 2). **INSERT TABLE 2 HERE Discussion** Elderly participants and high social desirability were significantly associated with high adherence based on trend analysis. Multiple linear regression analysis showed that high MTX adherence in RA patients is associated with high social desirability, high educational level, and non-full-time work. In our study, only 27.9% of the participants showed high medication adherence. Several studies reported that adherence to DMARDS was 40%-107% [9,33,34]. There are several potential reasons for the observed low adherence. First, the method of adherence measurement in each study was different. There were interviews, questionnaires, tablet count, drug concentration, and doctor's judgment as

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

measurements. A previous study showed that the adherence to interview, tablet count, drug concentration, and doctor's judgment were 96%, 77%, 58%, and 42%, respectively, which showed vast differences [35]. Since each measurement has advantages and disadvantages, the gold standard is not determined. We chose a self-reported questionnaire in this study since this scale is not expensive or invasive and can be possibly validated. Second, the time point of adherence measurement was different between the studies. We measured adherence during the maintenance period (mean disease duration, 53 months). A previous report suggested that the adherence of DMARDs in the early period was low (58%) [5]. Another study reported the adherence to salazosulfapyridine as 87% at three years from the start of medication [30]. In contrast, the adherence to DMARDs in the maintenance period varied from 84%, 470% [36], to 95.4% [37]. Previous reports have suggested that the adherence to DMARDs was not different between the early and maintenance periods. It is crucial to note that the time point of measuring medication adherence is the maintenance period because RA is a chronic disease that requires DMARDs for a long duration. The third is the difference in participant characteristics. Living status and marital status affected

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

adherence [10,38]. Our study could not adjust the living status and marital status because we could not include more factors based on our sample size. In addition, the age of the participants may have had an effect. In the original MMAS-8 article [26], the mean age was 52 years; however, in our study, the median age was 64 years, which means that the participants in our study were older, and this may have influenced the results. Furthermore, older people may not have revealed the truth. Thus, when referring to drug adherence studies, the method of measuring adherence, whether the target patient is in the disease's early or maintenance phase, and the patient's characteristics should be confirmed before adaptation. Our study detected high social desirability, high educational level, and non-full-time work as factors affecting MTX adherence. A previous study reporting MTX adherence found that adherence is associated with age, sex, race, RA disease activity, patient beliefs about the medication, disease duration, mental health, and SES. The discrepancy between our findings and those of other studies could be attributed to three reasons. First, we measured and adjusted social desirability, which possibly affected the answers in the questionnaire. Although a recent MTX adherence research mentioned the

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

necessity to account for this bias [15], no studies have examined how MTX adherence survey accounts for social desirability. The results may have differed since we conducted a factor search that included social desirability. Second, racial differences may have led to different outcomes. Our study was based on a Japanese population; however, previous studies were mainly on white people, black people, and Hispanic people. Canon et al. reported that the adherence to MTX was associated with the Caucasian race [4]. Therefore, adherence may be influenced by race. Third, the definition of medication adherence varies between studies. We used MMAS-8 in our study. Conversely, previous studies used other methods to assess medication adherence, such as physicians' estimation, different self-reported scales, drug concentration, tablet count electronic monitors, and other questionnaires. A prior study reported that medication adherence differs because the measurement method employed seems to vary [11]. Therefore, we need to practice caution when using research results because the results may differ depending on the method of measuring adherence and the variables incorporated, including social desirability. Our study demonstrated that RA patients with high social desirability had high MTX

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

adherence. A previous study reported that social desirability refers to responding to self-reported items that make the respondent seem better [12]. Contrastingly, the influence of social desirability is unknown, although its significance is generally accepted. A previous report has suggested that social desirability does not play a major role in assessing subjective well-being [39]. Therefore, although the effect of social desirability on drug adherence may not be significant, we were able to search for factors that consider social desirability. Our study had three strengths. First, we assessed social desirability, leading to social desirability bias. To our knowledge, no clinical studies adjusting social desirability have investigated the association between MTX adherence and various factors. Second, to our knowledge, this is the first research to examine MTX adherence in an Asian population. Third, the response rate to the questionnaires was high (93.4%), thereby strengthening internal validity. This study has significant implications for the clinician. Our findings may prevent unnecessary DMARDs changes since physicians tend to overestimate patients' medication adherence [40]. They should confirm MTX adherence before switching or

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

adding DMARDS. Accordingly, this provides an opportunity to reduce the healthcare cost and adverse events of medication. However, this study had several limitations. First, in the multivariable analysis, some immeasurable essential factors (such as characteristics of each participant, joint deformities, number of medications, and MTX dosing frequency) that could affect MTX adherence possibly exist. We did not determine patient personality due to the difficulty in quantifying it. In addition, we did not collect radiographs even if they are necessary for determining joint deformity because they are burdensome for patients. However, we adjusted for joint deformity using the mHAQ to reduce its possible influence on the findings. In addition, although the number of MTX doses was collected, it was not possible to incorporate variables due to sample size limitations. Second, the generalizability of our findings is limited. Our study setting was primarily university hospitals in Japan; thus, the results of this study cannot be applied to the clinical setting, in small- and medium-sized hospitals, or in settings including other races. Furthermore, the highest dose of MTX in Japan in the study was 8 mg per week. This dose is less than the standard dose of 20 mg worldwide, which limits the indications. Third, we used

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

a self-reported questionnaire of adherence. Hence, the completed questionnaire possibly influenced social desirability. Although we could not adjust this bias completely, social desirability was added as a factor for analysis. **Conclusions** Our results demonstrated that sixty percent of the RA patients had moderate adherence to MTX. Moreover, high MTX adherence in RA patients is associated with high social desirability, high educational level, and non-full-time work. **List of Abbreviations** ADL: Activities of Daily Living BMQ: Beliefs about Medicines Questionnaire **BPI**: Brief Pain Inventory CES-D: Center for Epidemiological Studies Depression DAS28-ESR: Disease Activity Score (28 joint count)-erythrocyte sedimentation rate DMARDs: disease-modifying antirheumatic-drugs MCS: mental component summary

344

346

348

349

350

351

352

354

355

356

358

mHAQ: modified Health Assessment Questionnaire MMAS-8: Morisky Medication Adherence Scale 345 MTX: methotrexate NRS: Numerical Rating Scale 347 PCS: physical component summary RA: rheumatoid arthritis SDS: Social Desirability Scale SF-8: 8-item Short-Form Health Survey **Declarations** 353 Ethics approval and consent to participate The ethics committee of Showa University Hospital (approval number 1446) and other each institution approved this study, and informed consent was obtained from all participants before study enrolment. All study procedures were performed in accordance 357 with the Declaration of Helsinki. Patient information was anonymized and de-identified before analysis.

360

361

362

364

366

367

368

369

370

371

372

374

Consent for publication Not applicable. Availability of data and materials The dataset analyzed in this paper is available from the corresponding author on 363 reasonable request. 365 **About MMAS8** The use of the MMAS diagnostic adherence assessment instrument is protected by US copyrighted and trademarked laws. Permission for use is required. A license is available from MORISKY MEDICATION ADHERENCE RESEARCH, LLC., Donald E. Morisky, ScD, ScM, MSPH, MMAR, LLC, 294 Lindura Ct., Las Vegas, NV 89138; dmorisky@gmail.com. Competing interests 373 Donald E. Morisky holds a copyright for the Morisky Medication Adherence Scale-8, is one of its authors, and collects fees in exchange for licenses to use the scale in research.

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

This does not alter the authors' commitment to objectivity in research or adherence to data sharing policies. He was not involved in any data analysis. For the remaining authors, none were declared. **Funding** The authors have not received funding to conduct this study. Authors' contributions Nobuyuki Yajima: Methodology, Project administration, Writing - original draft, Writing – Review & Editing Takashi Kawaguchi: Supervision, Conceptualization, Project Administration, Writing – original draft, Writing – Review & Editing Ryo Takahashi: Data curation, Writing – original draft, Writing – Review & Editing Hiroki Nishiwaki: Data curation, Writing – original draft, Writing – Review & Editing Youichi Toyoshima: Data curation, Writing – original draft, Writing – Review & Editing Koei O: Data curation, Writing – original draft, Writing – Review & Editing Tsuyoshi Odai: Data curation, Writing – original draft, Writing – Review & Editing Takayuki Kanai: Data curation, Writing – original draft, Writing – Review & Editing

391 Donald E. Morisky: Supervision, Writing – original draft, Writing – Review & Editing 392 Takuhiro Yamaguchi: Formal Analysis, Supervision, Writing – original draft, Writing – 393 Review & Editing 394 Tsuyoshi Kasama: Supervision, Writing – original draft, Writing – Review & Editing 395 Acknowledgments 396 We thank Noboru Murata (Kikuna Memorial Hospital) and Osamu Namiki for critically 397 reviewing the manuscript. 398 399 Authors' information 400 Division of Rheumatology, Department of Medicine, Showa University School of 401 Medicine, Tokyo, Japan 402 Nobuyuki Yajima, Ryo Takahashi, Tsuyoshi Kasama 403 Department of Healthcare Epidemiology, Kyoto University Graduate School of 404 Medicine and Public Health, Kyoto, Japan 405 Nobuyuki Yajima

406 Center for Innovative Research for Communities and Clinical Excellence, 407 Fukushima Medical University, Fukushima, Japan 408 Nobuyuki Yajima 409 Department of Practical Pharmacy, School of Pharmacy, Tokyo University of 410 Pharmacy and Life Sciences, Tokyo, Japan 411 Takashi Kawaguchi 412 Division of Nephrology, Department of Internal Medicine, Showa University 413 Fujigaoka Hospital, Yokohama, Japan 414 Hiroki Nishiwaki 415 Showa University Research Administration Center, Tokyo, Japan 416 Hiroki Nishiwaki 417 Department of Orthopedic Surgery, Showa University Toyosu Hospital, Tokyo, 418 Japan 419 Yoichi Toyoshima Department of Orthopedic Surgery, Showa University Northern Yokohama 420 421 Hospital, Yokohama, Japan

422 Koei Oh 423 Department of Internal Medicine, Showa University Northern Yokohama Hospital, 424 Yokohama, Japan 425 Tsuyoshi Odai 426 Department of Rheumatology, Yokohama Asahi Central General Hospital, 427 Kanagawa, Japan. 428 Tsuyoshi Odai 429 Department of Nephrology, Kanto Rosai Hospital, Kawasaki, Japan 430 Takayuki Kanai 431 Department of Community Health Sciences, UCLA Fielding School of Public 432Health 433 Donald E. Morisky 434 Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, 435 Japan 436 Takuhiro Yamaguchi

References

437

- 438 1. van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof
- MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a
- three-year prospective followup of patients with early rheumatoid arthritis. Arthritis
- 441 Rheum. 1992;35:26-34.
- 442 2. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al.
- 443 2015 American College of Rheumatology Guideline for the treatment of rheumatoid
- arthritis. Arthritis Care Res (Hoboken). 2016;68:1-25.
- 3. Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M,
- Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid
- arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019
- 448 update. Ann Rheum Dis. 2020;79:685-99.
- 449 4. Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, et al.
- Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess
- methotrexate adherence and disease activity in clinical practice. Arthritis Care Res
- 452 (Hoboken). 2011;63:1680-90.

- 5. Contreras-Yanez I, Ponce De Leon S, Cabiedes J, Rull-Gabayet M,
- Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in
- patients with rheumatoid arthritis who have achieved remission with
- disease-modifying antirheumatic drugs. Am J Med Sci. 2010;340:282-90.
- 6. De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants
- 458 of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol.
- 459 2016;35:1335-9.
- 460 7. DiBenedetti DB, Zhou X, Reynolds M, Ogale S, Best JH. Assessing
- methotrexate adherence in rheumatoid arthritis: a cross-sectional survey. Rheumatol
- 462 Ther. 2015;2:73-84.
- 8. Salt E, Frazier SK. Adherence to disease-modifying antirheumatic drugs in
- patients with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs.
- 465 2010;29:260-75.
- 9. Scheiman-Elazary A, Duan L, Shourt C, Shourt C, Agrawal H, Ellashof D, et al.
- The rate of adherence to antiarthritis medications and associated factors among
- 468 patients with rheumatoid arthritis: a systematic literature review and metaanalysis. J

- 469 Rheumatol. 2016;43:512-23.
- 470 10. Waimann CA, Marengo MF, de Achaval S, Cox VL, Garcia-Gonzalez A,
- Reveille JD, et al. Electronic monitoring of oral therapies in ethnically diverse and
- economically disadvantaged patients with rheumatoid arthritis: consequences of low
- 473 adherence. Arthritis Rheum. 2013;65:1421-9.
- Hope HF, Bluett J, Barton A, Hyrich KL, Cordingley L, Verstappen SM.
- 475 Psychological factors predict adherence to methotrexate in rheumatoid arthritis;
- findings from a systematic review of rates, predictors and associations with
- patient-reported and clinical outcomes. RMD Open. 2016;2:e000171.
- Holtgraves T. Social desirability and self-reports: testing models of socially
- desirable responding. Pers Soc Psychol Bull. 2004;30:161-72.
- 480 13. Hebel S, Kahn-Woods E, Malone-Thomas S, McNeese M, Thornton L,
- Sukhija-Cohen A, et al. Brief report: discrepancies between self-reported adherence
- and a biomarker of adherence in real-world settings. J Acquir Immune Defic Syndr.
- 483 2020;85:454-7.
- 484 14. van der Straten A, Montgomery ET, Hartmann M, Minnis A. Methodological

- lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep.
- 486 2013;10:89-102.
- 487 15. Aaltonen KJ, Turunen JH, Sokka T, Puolakka K, Valleala H. A survey on the
- medication adherence to methotrexate among rheumatoid arthritis patients treated with
- self-administered biologic drugs. Clin Exp Rheumatol. 2016;34:694-7.
- 490 16. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al.
- 491 2010 rheumatoid arthritis classification criteria: an American College of
- Rheumatology/European League against Rheumatism collaborative initiative. Arthritis
- 493 Rheum. 2010;62:2569-81.
- 17. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB,
- van Riel PL. Modified disease activity scores that include twenty-eight-joint counts.
- Development and validation in a prospective longitudinal study of patients with
- rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
- 498 18. Radloff LS. The CES-D scale: a self-report depression scale for research in the
- general population. Appl Psychol Meas. 1977;1:385-401.
- Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role

- in adherence to treatment in chronic physical illness. J Psychosom Res.
- 502 1999;47:555-67.
- 503 20. Crowne DP, Marlowe D. A new scale of social desirability independent of
- psychopathology. J Consult Psychol. 1960;24:349-54.
- 505 21. Reynolds WM. Development of reliable and valid short forms of the
- 506 Marlowe-Crowne social desirability scale. J Clin Psych. 1982;38:119-25.
- 507 22. Ware JE, GlaxoSmithKline. How to score and interpret single-item health
- status measures: a manual for users of the of the SF-8 health survey: (with a
- supplement on the SF-8 health survey). Lincoln, RI; QualityMetric, Inc.; Boston, MA:
- Health Assessment Lab. 2001.
- 511 23. Birrell FN, Hassell AB, Jones PW, Dawes PT. How does the short form 36
- health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome
- measures and SF-36 population values? A cross-sectional study. Clin Rheumatol.
- 514 2000;19:195-9.
- 515 24. Iihara N, Suzuki K, Kurosaki Y, Morita S, Hori K. Factorial invariance of a
- questionnaire assessing medication beliefs in Japanese non-adherent groups. Pharm

- 517 World Sci. 2010;32:432-9.
- 518 25. Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain
- assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory--BPI-J. J
- 520 Pain Symptom Manage. 1998;16:364-73.
- 521 26. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a
- medication adherence measure in an outpatient setting. J Clin Hypertens. (Greenwich)
- 523 2008;10:348-54.
- 524 27. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, et al.
- 525 Effect of intensive blood-pressure treatment on patient-reported outcomes. N Engl J
- 526 Med. 2017;377:733-44.
- 527 28. Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, et al.
- 528 Cost-effectiveness of intensive versus standard blood pressure control. N Engl J Med.
- 529 2017;377:745-55.
- 530 29. Lorish CD, Richards B, Brown S. Missed medication doses in rheumatic
- arthritis patients: intentional and unintentional reasons. Arthritis Care Res. 1989;2:3-9.
- 532 30. Brus HL, van de Laar MA, Taal E, Rasker JJ, Wiegman O. Effects of patient

- education on compliance with basic treatment regimens and health in recent onset
- active rheumatoid arthritis. Ann Rheum Dis. 1998;57:146-51.
- 535 31. Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T, van den Heuvel W.
- Compliance with drug therapy in rheumatoid arthritis. A longitudinal European study.
- 537 Joint Bone Spine. 2000;67:178-82.
- 538 32. Cohen, J. A power primer. Psychol Bull. 1992;112:155-9.
- 539 33. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in
- patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert
- 541 Rev Clin Immunol. 2012;8:337-51.
- 542 34. Curtis JR, Bykerk VP, Aassi M, Schiff M. Adherence and persistence with
- 543 methotrexate in rheumatoid arthritis: a systematic review. J Rheumatol.
- 544 2016;43:1997-2009.
- 545 35. Pullar T, Peaker S, Martin MF, Bird HA, Feely MP. The use of a
- 546 pharmacological indicator to investigate compliance in patients with a poor response to
- antirheumatic therapy. Br J Rheumatol. 1988;27:381-4.
- 548 36. van den Bemt BJ, den Broeder AA, van den Hoogen FH, Benraad B, Hekster

YA, van Riel PL, et al. Making the rheumatologist aware of patients' non-adherence

- does not improve medication adherence in patients with rheumatoid arthritis. Scand J
 Rheumatol. 2011;40:192-6.

 7 Park DC, Hertzog C, Leventhal H, Morrell RW, Leventhal E, Birchmore D, et
 al. Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr

 7 Soc. 1999;47:172-83.
- 555 38. De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants
- of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol.
- 557 2016;35:1335-9.

549

- 558 39. McCrae RR. Well-being scales do not measure social desirability. J Gerontol.
- 559 1986;41:390-2.

564

- 560 40. Gossec L, Molto A, Romand X, Puyraimond-Zemmour D, Lavielle M,
- Beauvais C, et al. Recommendations for the assessment and optimization of adherence
- to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process
- based on literature reviews and expert consensus. Joint Bone Spine. 2019;86:13-19.

Figure Legend

Figure 1. Patient flow chart

Tables

Table 1. Patient characteristics by grade of MTX adherence divided by MMAS-8 (n=165)

		MMAS-8			
	All	Low	Medium	High	— p
	(n=165)	(n=20)	(n=99)	(n=46)	value
Age, median (IQR)	64	58	65	65.5	0.01

	(54–72)	(44–62)	(53–73)	(59–74)	
Female, n (%)	142 (86.1)	18 (90.0)	84 (84.6)	38 (82.6)	0.74
MTX dose (mg/week),	8 (6–12)	10 (8–12)	8 (6–10)	10 (8–12)	0.17
median (IQR)	0 (0-12)	10 (0–12)	0 (0–10)	10 (0–12)	0.17
MTX dosing frequency					
(times/week), median	3 (2–3)	3 (2–3)	2 (2–3)	2 (2–3)	0.54
(IQR)					
Duration of MTX					
treatment	36 (17–75)	32 (16–79)	35 (18–80)	41 (13–74)	0.15
(month), median (IQR)					
Disease duration	53.5	35	47	60.5	0.05
(month), median (IQR)	(22.5–123.5)	(22–120)	(22–111)	(24–158)	0.95
Concomitant medication					
NSAIDS, n (%)	59 (35.8)	5 (25.0)	36 (36.4)	8 (39.1)	0.53
Corticosteroid, n (%)	27 (16.4)	2 (10.0)	17 (17.2)	8 (17.4)	0.71
Biologics, n (%)	48 (29.1)	7 (35.0)	28 (28.3)	13 (28.3)	0.83
DAS28-ESR, median	2.30	2.01	2.32	2.40	0.08
(month), median (IQR) Disease duration (month), median (IQR) Concomitant medication NSAIDS, n (%) Corticosteroid, n (%) Biologics, n (%) DAS28-ESR, median (IQR) mHAQ, median (IQR) BMQ necessity-concern differential, median (IQR) CES-D (total score ≥16), n (%) BPI (average NRS pain	(1.68–3.00)	(1.37–2.23)	(1.68–3.02)	(2.01–3.15)	
	0	0	0	0.13	0.02
mhaQ, median (IQR)	(0-0.13)	(0-0.25)	(0-0)	(0-0.38)	0.02
BMQ necessity-concern	1 (0, 2)	2 (0, 2)	1 (0, 2)	2 (0, 2)	0.81
differential, median (IQR)	1 (0–3)	2 (0–3)	1 (0–3)	2 (0–3)	0.81
CES-D (total score \geq 16), n	27 (26.4)	9 (47 1)	21 (9.2)	9 (20 0)	0.10
(%)	37 (26.4)	8 (47.1)	21 (8.3)	8 (20.0)	0.10
BPI (average NRS pain	2 (1 2)	1 (1 4)	1 (1 2)	1 (2 4)	0.12
score), median (IQR)	2 (1–3)	1 (1–4)	1 (1–3)	1 (3–4)	0.13
SDS, median (IQR)	6 (4–7)	4 (3–6)	6 (4–6)	6.5 (5–8)	0.00
CE 0 (DCC) Har (IOD)	48.1	47.4	49.8	45.6	0.04
SF-8 (PCS), median (IQR)	(42.4–52.1)	(45.8–52.1)	(43.5–52.1)	(40.2–50.2)	0.04
	50.2	47.7	50.3	50.0	0.26
SF-8 (MCS), median (IQR)	(45.6–54.1)	(43.0–53.2)	(46.3–53.9)	(46.1–55.0)	0.36
Marital status (married), n	05 (57 0)	11 (55.0)	61 (62.2)	22 (50.0)	0.27
(%)	95 (57.9)	11 (55.0)	61 (62.2)	23 (50.0)	0.37
Educational level (greater	36 (21.8)	5 (25.0)	17 (17.2)	14 (30.4)	0.19

than or equal to college					
level), n (%)					
Employment status	38 (23.0)	12 (60.0)	22 (22.2)	4 (8.7)	0.00
(full-time), n (%)	36 (23.0)	12 (00.0)	22 (22.2)	4 (6.7)	0.00
Living status (living alone),	43 (26.4)	7 (35.0)	24 (24.5)	12 (26.7)	0.62
n (%)	43 (20.4)	7 (33.0)	24 (24.3)	12 (20.7)	0.02

IQR, interquartile range; DAS28-ESR, Disease Activity Score (28 joint count)- erythrocyte sedimentation rate; mHAQ, modified Health Assessment Questionnaire; BMQ, Beliefs about Medicines Questionnaire; CES-D, Center for Epidemiological Studies Depression; BPI, Brief Pain Inventory; NRS, Numerical Rating Scale; SDS, Social Desirability Scale; SF-8, 8-item Short-Form Health Survey; PCS, physical component summary; MCS, mental component summary; MTX, methotrexate; MMAS-8, Morisky Medication Adherence Scale

Table 2. Factors associated with MTX adherence using linear regression analysis (n=165)

	Coef.	95% CI	p value	
Age	0.02	0.00-0.03	0.03	
Female	-0.09	-0.58-0.40	0.73	
Disease duration	0.00	-0.00-0.00	0.41	
RA activity (DAS28-ESR)	0.16	-0.03-0.35	0.09	
Depression state (CES-D)	-0.26	-0.69-0.18	0.25	
Belief about medicine	0.01	-0.07-0.09	0.86	
(BMQ necessity-concern differential)	0.01	-0.07-0.09		
Social desirability (SDS)	0.14	0.05-0.23	0.00	
Educational level (more than or equal to	0.36	-0.10-0.82	0.13	
college level or not)		-0.10-0.82	0.13	
Employment status	-0.50	-0.950.05	0.03	
(full-time work or not)	-0.30	-0.750.03	0.03	

MTX, methotrexate; RA, rheumatoid arthritis; DAS28-ESR, Disease Activity Score (28 joint count)-erythrocyte sedimentation rate; BMQ, Beliefs about Medicines Questionnaire; CES-D, Center for Epidemiological Studies Depression; SDS, Social Desirability Scale; Coef, regression coefficients; CI, confidence interval



